ReviewEuropean journal of nuclear medicine and molecular imaging2017
Therapy assessment in prostate cancer using choline and PSMA PET/CT.
Review in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- [Molecular imaging and biology · 2025Trial
- Integrated spatial transcriptome and metabolism study reveals metabolic heterogeneity in human bladder cancer.Cancer gene therapy · 2025Article
- Review
- Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer.Cancers · 2022Review
- E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET.European journal of nuclear medicine and molecular imaging · 2021Article
- Combination ofCancer management and research · 2021Article
- Article
- ImmunoPET: Concept, Design, and Applications.Chemical reviews · 2020Review
- Determination of split renal function by PSMA imaging: comparison ofAmerican journal of nuclear medicine and molecular imaging · 2020Article
- Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news.Ecancermedicalscience · 2020Review
- [EJNMMI research · 2019Article
- Pseudoprogression on PSMA PET imaging of a mCRPC patient under anti-PD1 treatment.European journal of nuclear medicine and molecular imaging · 2019Article
- The influence of PSA flare in mCRPC patients treated with alpha-emitting radiopharmaceuticals.European journal of nuclear medicine and molecular imaging · 2018Article
- Clinical perspectives of PSMA PET/MRI for prostate cancer.Clinics (Sao Paulo, Brazil) · 2018Review
- Uptake of Radium-223 Dichloride and Early [Molecular imaging and biology · 2018Article
- Advances in prostate-specific membrane antigen PET of prostate cancer.Current opinion in oncology · 2018Review
- Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis.European journal of nuclear medicine and molecular imaging · 2018Article
- Positron Emission Tomography Imaging of Prostate Cancer with Ga-68-Labeled Gastrin-Releasing Peptide Receptor Agonist BBNBioconjugate chemistry · 2018Article
- Therapy monitoring with PET in cancer patients: achievements, opportunities and challenges ahead for the PET community.European journal of nuclear medicine and molecular imaging · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While PET with non-FDG tracers (mainly choline and Ga-PSMA) has commonly been used for restaging in men with biochemically recurrent prostate cancer, as well as for primary staging, it is only recently that a few preliminary studies have addressed the possible use of PET for monitoring the response to systemic therapy of metastatic disease, especially innovative treatments such as abiraterone and enzalutamide. This article aims to evaluate the role of PET imaging with different non-FDG radiotracers for assessment of therapy in advanced prostate cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.